WORLD PEPTIDEFOUNDATION
← Master Registry

Published peptide research references

Pegozafermin

Governed registry record

4 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Approved source records

  1. NAFLD and NASH: etiology, targets and emerging therapies.

    DOI: 10.1016/j.drudis.2024.103910PMID: 38301798

    Source identity and connection checked by Codex (AI).

  2. Pegozafermin Is a Potential Master Therapeutic Regulator in Metabolic Disorders: A Review.

    DOI: 10.1097/crd.0000000000000625

    Source identity and connection checked by Codex (AI).

  3. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.

    DOI: 10.1056/nejmoa2304286

    Source identity and connection checked by Codex (AI).

  4. The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers.

    DOI: 10.1124/jpet.123.001618

    Source identity and connection checked by Codex (AI).

Legacy research context

Context from the legacy curated dataset. Its counts describe that dataset and are separate from the live approved source records above.

Researchers represented

  • Loomba R
  • Sanyal AJ
  • Kowdley KV
  • Bhatt DL
  • Alkhouri N
  • Frias JP
  • Bedossa P
  • Harrison SA
  • Lazas D
  • Barish R
  • Gottwald MD
  • Feng S
  • Agollah GD
  • Hartsfield CL
  • Mansbach H
  • Margalit M
  • Abdelmalek MF
  • Bailey NN
  • Peterson SJ
  • Parikh MA
  • Jackson KA
  • Frishman WH
  • Rosenstock M
  • Tseng L
  • Pierce A
  • Offman E
  • Chen CY
  • Charlton RW
  • Wei S
  • Wang L
  • Evans PC
  • Xu S